The FDA may continue the Expedited Access Pathway Program (EAP). If this program is continued in the new administration, it represents an opportunity for innovative treatments that meet un-met medical needs. The program which started in 2014 allows for devices that are of reasonable risk to be marketed with post market testing. As part of […]